Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
about
Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO BiochemistryO2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studiesDifferential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.Photoinduced release of nitroxyl and nitric oxide from diazeniumdiolatesPolymer-Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications.Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganismsPhotoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors.Synergy of nitric oxide and silver sulfadiazine against gram-negative, gram-positive, and antibiotic-resistant pathogens.Integration of molecular and enzymatic catalysts on graphene for biomimetic generation of antithrombotic speciesAnalysis of the HNO and NO donating properties of alicyclic amine diazeniumdiolates.Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status.HNO and NO release from a primary amine-based diazeniumdiolate as a function of pHNovel device for continuous spatial control and temporal delivery of nitric oxide for in vitro cell cultureNitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT).Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia.Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1Mechanism of pH-dependent decomposition of monoalkylamine diazeniumdiolates to form HNO and NO, deduced from the model compound methylamine diazeniumdiolate, density functional theory, and CBS-QB3 calculationsExamination of bacterial resistance to exogenous nitric oxide.Improved in vivo performance of amperometric oxygen (PO2) sensing catheters via electrochemical nitric oxide generation/release.The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis.Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential.Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia.Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.Long-term effect of PROLI/NO on cellular proliferation and phenotype after arterial injury.High-level theoretical study of the NO dimer and tetramer: has the tetramer been observed?NO supplementation for transfusion medicine and cardiovascular applicationsDiazeniumdiolate reactivity in model membrane systems.Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia.Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primatesMorphological analysis of the antimicrobial action of nitric oxide on gram-negative pathogens using atomic force microscopy.Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury.Sex-based differential regulation of oxidative stress in the vasculature by nitric oxideEffects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.CellNO trap: Novel device for quantitative, real-time, direct measurement of nitric oxide from cultured RAW 267.4 macrophagesInorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide Delivery Scaffold.Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress.Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compoundSynthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.Prolonged NO treatment decreases alpha-adrenoreceptor agonist responsiveness in porcine pulmonary artery due to persistent soluble guanylyl cyclase activation.
P2860
Q27702646-E1762392-B207-473D-9C81-EE47DCFEA6E6Q28210989-5535F566-1ED3-49B6-BDA9-25F235C4BBB7Q30428613-B0B4DCAA-AA94-4E4B-83C8-A4FB5C0CA439Q33284032-D183722E-122B-4315-BA33-FC3ADF16A05BQ33951477-32F45DA0-A8DE-4890-AF4C-BB8C4A230ED9Q34160541-3A7C9CB2-CB53-42E1-8879-4CD743A3AC28Q34259551-F53671C9-3A2F-4809-9750-EBBEBC5F8EA8Q34384513-A250DA99-8094-4C2D-B3DE-73A5D9A11171Q34598197-226C0735-81C3-4CF9-95B5-E1D268F22E7DQ34646634-4E0CEF23-01D2-4A76-A1F9-A382E47DA52BQ34762218-BA87971F-AF36-4760-B39B-F4579DA17DAFQ34785768-DCEF3666-1C47-4DB1-9FB3-9EFB8C71644CQ34984805-7597E03A-FB26-4C4C-901E-A5605AAFB162Q35047597-7646A1A5-CC50-447D-8921-A20F7BED41C1Q35058371-22AF25A9-14B4-4EE8-88EF-CCAE02D7071FQ35163743-A57CDC5D-A766-4992-8E80-D7EB507E74CBQ35187446-0C74C4F5-A356-4CCB-B8D4-E8F18F468940Q35872644-42D84AA4-1FCB-466D-B087-667D2A9D4AF3Q36015181-5358E482-FE24-4774-A1B0-0DBC435491C4Q36168425-1E3FF3C3-3278-45E8-97AB-6819599B2D99Q36196462-3DBD8094-3A8C-40CF-94B2-401E8A4F0E91Q36327570-FB0F6D75-9B02-4FFB-AE43-3C5597B21EC8Q36393262-9F07E6F4-1859-4BC3-BCFD-99E87A2E7FD6Q36421859-6F052060-510B-4177-A3B0-CF519449A52AQ36484151-B6819FB3-81A0-4577-A8C1-A8FE17CA6A3FQ36490497-33678B63-0E4D-4C87-B1F7-950FDDBF3A10Q36497059-7C9D715F-7A47-4F01-A0CA-F8056E64A99DQ36497132-7925246B-468D-48F5-A2B5-FC16DF36806BQ36516264-E28664C5-99AE-4F2A-B4AB-FF4300F9DA0EQ36567227-D928ACAD-7805-4A12-BACD-2ABA8DD78410Q36615899-16EE6E44-B01E-4831-B4D0-41987DE13D98Q36661502-8CAC24F9-0509-425C-AB68-5CC85C1DC3C7Q36717790-7B9FE794-A371-45BB-87DF-9D7CAD6F8952Q36741601-25955215-916C-4E96-A696-3031AB993F82Q36787576-9FEE7CC9-348B-4E3F-874E-F1A2297201A7Q36977563-20853250-F947-4D35-83E0-F0EC6FCEF1A4Q37029859-95299A4D-1219-4F11-BB2E-DA08BB97D0A8Q37074663-9A6C2F67-E7D8-4556-9985-C7757CAA58CEQ37074670-00552362-028D-4FAC-8212-2C2DCAC277B7Q37162742-147F17B6-2724-46A3-BDB3-70ACADF10BE8
P2860
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@ast
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@en
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@nl
type
label
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@ast
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@en
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@nl
prefLabel
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@ast
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@en
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@nl
P1476
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
@en
P2093
Larry K Keefer
P304
P356
10.1146/ANNUREV.PHARMTOX.43.100901.135831
P577
2002-01-10T00:00:00Z